INS and obesity disorder: Preclinical testing of desHis1Glu9-glucagon and desHis1Glu9(Lys30PAL)-glucagon in HFF obese mice reversed obesity-driven hyperinsulinaemia and insulin resistance together with improvements in lipid profile, glucose tolerance and increased pancreatic insulin stores (345).